Skip to main content

Month: May 2023

Santhera Publishes Annual Report 2022

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022. Santhera’s Annual Report 2022 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2022, and confirms the preliminary unaudited 2022 annual results which were published on April 27, 2023. The Annual Report 2022 is available for download on the Company’s website at www.santhera.com/financial-reports. Corporate calendarJune 27, 2023        Annual General Meeting About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative...

Continue reading

Shawcor Secures Five Pipe Coating Contract Awards and One Letter of Intent, Collectively Valued at Over $150M

TORONTO, May 31, 2023 (GLOBE NEWSWIRE) — Shawcor Ltd. (TSX: SCL) (“Shawcor” or the “Company”) announced today that its pipe coating division, Pipeline Performance Group (“PPG”), has received five formal contract awards and one letter of intent (“LOI”) for development projects in South America, Mexico and the Ivory Coast. The coating value of these projects collectively exceeds $150M. These commitments include:Two Purchase Orders (“PO”) for the provision of insulation coating services on South American offshore projects. These projects were previously announced as being under a letter of intent (“LOI”). Project initiation is expected to begin in the second quarter of 2024 and extend into 2025. One PO for the provision of insulation coating services on a South American offshore project. This project will utilize Shawcor’s proprietary...

Continue reading

P2 Gold Closes Second Tranche of Non-Flow-Through Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) (OTCQB:PGLDF) reports that it has closed the second tranche (the “Second Tranche”) of its non-brokered private placement of non-flow-through units (the “Units”) at $0.27 per Unit, for gross proceeds of up to approximately $1.5 million (the “Offering”), previously announced on April 5, 2023 and May 4, 2023. The Second Tranche consisted of 785,632 Units for gross proceeds of approximately $212,000. Each Unit consists of one non-flow-through common share in the capital of the Company and one non-flow-through common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional non-flow-through...

Continue reading

eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced today that it has closed its previously announced registered direct offering for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.655 per share (or common stock equivalent in lieu thereof), priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 11,450,382 shares of common stock with an exercise price of $0.53 per share which are immediately exercisable for a period of five and one-half years following...

Continue reading

BioSyent Announces Approval of New Product

MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product. BioSyent Pharma Inc. signed an exclusive Canadian Distribution Agreement for this product with a European partner in December 2022. “We are pleased to have received marketing approval for this new product, bringing it one step closer to launch in Canada,” said René Goehrum, President and CEO of BioSyent. “We look forward to entering the oncology supportive care therapeutic area with this new product which enhances our specialty product portfolio and contributes to our ongoing growth.”       About BioSyent Inc. Listed on the TSX Venture Exchange under the trading...

Continue reading

D-BOX Technologies Reports Fourth Quarter and Fiscal 2023 Year End Results

Fourth quarter revenue growth caps strongest year in four yearsTotal revenues grew 60% to $34.1 million for the year, including 49% growth in the fourth quarter System sales revenues increased 63% to $25.6 million for the year, including 57% growth in the fourth quarter Rights for use, rental and maintenance revenues grew 53% to $8.5 million for the year, including 22% growth in the fourth quarter Adjusted EBITDA* was $1.8 million for the year, including $0.6 million in the fourth quarter Net loss decreased to $0.9 million for the year and was $0.1 million in the fourth quarterMONTRÉAL, May 31, 2023 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, today reported financial results for the fourth quarter and fiscal year ended March 31,...

Continue reading

Descartes Announces Fiscal 2024 First Quarter Financial Results

Record Revenues and Income from Operations WATERLOO, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) announced its financial results for its fiscal 2024 first quarter (Q1FY24). All financial results referenced are in United States (US) currency and, unless otherwise indicated, are determined in accordance with US Generally Accepted Accounting Principles (GAAP). “The Global Logistics Network (GLN) continues to help shippers, carriers and logistics services providers benefit from more efficient supply chains and logistics operations,” said Edward J. Ryan, Descartes’ CEO. “Our customers’ successes with the GLN have put us in a strong position to continue to invest in our business for the future. We continue to add more services for our customers to manage the complete lifecycle of...

Continue reading

Telesis Bio Secures Financing of $28.0 Million

Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds. The financing...

Continue reading

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to July 3, 2023

MIAMI, May 31, 2023 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that its sponsor, Vision Sensing, LLC, has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from June 3, 2023 to July 3, 2023 by depositing into the Company’s trust account an aggregate of $72,562.86 (the “Extension”). In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $72,562.86 as consideration for the funding. This will be the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate...

Continue reading

AS PRFoods Unaudited Consolidated Interim Report 3d Quarter and 9 months 2022/23

Consolidated Unaudited Interim Report of AS PRFoods for the 3rd quarter and 9 months of 2022/2023 financial year PRFoods continues to operate now as Estonian-British group, having two productions facilities in Estonia and United Kingdom respectively. Fish farming operations are taking place only in Estonia, with further capacity expansions planned. Q3 and 9 months results show that downsizing operations was risky but proven right, as our profitability has substantially improved. EBITDA from operations improved from -1,1 meur year ago to 0,04 meur. Operating results was near zero when last year it was still -1,4 meur. We finished quarter with small profit compared to -4,5 meur loss last year (due to divestments). On 9 months basis our EBITDA from operations improved from -2,3 meur to 200,000 eur positive result, , while our sales were down...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.